Chinese Traditional and Herbal Drugs
|
2025, 56(15): 5519-5528
Quality evaluation of Epimedii Folium based on anti-inflammatory biological potency
Full
LU Zongliang1,2,3, LI Chengwei2,3,4, WEN Jincai2,3, ZHAN Xiaoyan2,3, XIAO Xiaohe2,3, BAI Zhaofang2,3,5
Affiliations
1 College of Food and Biological engineering, Chengdu University, Chengdu 610106, China; 2 China Military Institute of Chinese Medicine, the Fifth Medical Center of PLA General Hospital, Beijing, 100039, China; 3 Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China; 4 College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; 5 State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing 100700, China
About Author:
中央本级重大增减支项目“名贵中药资源可持续利用能力建设项目 (2060302); 国家自然科学基金重点项目 (U23A20519)
doi: 10.7501/j.issn.0253-2670.2025.15.017
Outline
Objective To establish a method for evaluating the quality of Yinyanghuo (Epimedii Folium) based on anti-inflammatory biological potency. Methods Immune-stimulatory DNA (ISD)-induced mouse bone marrow-derived macrophages (BMDMs) were used as an inflammatory cell model, and the anti-inflammatory effects of Epimedii Folium were preliminarily verified by detecting the protein expression levels of phosphorylated stimulator of interferon genes (p-STING), phosphorylated interferon regulatory factor 3 (p-IRF3) and the expression of type I interferon (IFN-β) combined with cell viability assay. Using STING inhibitor H151 as a positive control, an anti-inflammatory biological potency assay was established with IFN-β inhibition rate as the evaluation index to evaluate the anti-inflammatory potency of Epimedii Folium samples of different varieties and batches. High performance liquid chromatography was used to determine the contents of six characteristic components (diphylloside A, epimedin A, epimedin B, epimedin C, icariin, baohuoside I) in 15 batches of Epimedii Folium samples of five varieties, and then exploring the correlations between anti-inflammatory potency and the contents of the characteristic components by correlation analysis methods. Results The extract of Epimedii Folium could inhibit the expression levels of p-STING, p-IRF3 and IFN-β, which were the activation indexes of cyclic GMP-AMP synthase (cGAS)-STING signaling pathway, proving that it had a good anti-inflammatory effect. The anti-inflammatory potency of 15 batches of Epimedii Folium samples ranged from 221.05 to 1 130.50 U/mL , and the average anti-inflammatory potency of different varieties in order of from high to low was Epimedium sagittatum (951.17 U/mL), E. koreanum (748.38 U/mL), E. brevicornu (746.71 U/mL), E. pubescens (728.18 U/mL) and E. acuminatum (528.87 U/mL), which indicated that E. sagittatum had a good anti-inflammatory biological potency, and the counterfeit E. acuminatum had lower anti-inflammatory potency than the four genuine ones. Correlation analysis showed there was a significant positive correlation between icariin and the anti-inflammatory potency of Epimedii Folium (r = 0.540, P < 0.05), suggesting that this component may play a major role in the anti-inflammatory activity. Conclusion A method for evaluating the quality of Epimedii Folium based on its anti-inflammatory biological potency was established, which can directly reflect the quality of different Epimedii Folium in terms of anti-inflammatory “superiority or inferiority”, and provide a reference for the quality evaluation of traditional Chinese medicines with anti-inflammatory properties.
Epimedii Folium
/
anti-inflammatory
/
biological potency
/
quality evaluation
/
correlation analysis
/
diphylloside A
/
epimedin A
/
epimedin B
/
epimedin C
/
icariin
/
baohuoside I
鲁宗良, 李成伟, 文金财, 湛小燕, 肖小河, 柏兆方.
基于抗炎生物效价的淫羊藿质量评价研究.
中草药,
2025
, 56
(15)
: 5519
-5528
.
DOI: 10.7501/j.issn.0253-2670.2025.15.017
LU Zongliang, LI Chengwei, WEN Jincai, ZHAN Xiaoyan, XIAO Xiaohe, BAI Zhaofang.
Quality evaluation of Epimedii Folium based on anti-inflammatory biological potency[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(15)
: 5519
-5528
.
DOI: 10.7501/j.issn.0253-2670.2025.15.017
Year 2025 volume 56 Issue 15
49
0
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.15.017
- Receive Date:2025-04-22
- Online Date:2026-11-12